SPPL2B

Across TCGA pan-cancer cohorts, SPPL2B RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of SPPL2B’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where SPPL2B RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SPPL2B is over-expressed in tumor, although a few such as THCA show the opposite, repressed pattern.

KIRC, BLCA, and LIHC are the cancer types where SPPL2B tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SPPL2B RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	All	+0.573	<.001	11	view →
BLCA	All	All	+0.717	<.001	10	view →
LIHC	Female	II,III,IV	+1.154	<.001	8	view →
STAD	Male	II,III,IV	+0.995	<.001	8	view →
COAD	All	All	+0.462	<.001	8	view →
HNSC	All	All	+0.377	.001	8	view →
LUSC	All	All	+0.437	<.001	5	view →
THCA	Male	II,III,IV	−0.343	.011	5	view →
READ	All	All	+0.606	.038	4	view →
CHOL	Male	All	+2.376	<.001	3	view →
ESCA	All	All	+0.778	.005	3	view →
KIRP	All	IV	+0.930	.005	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

SPPL2B–KIRC

Open the KIRC breakdown →